Eleven members of the committee voted in favor of the recommendation and three were reused.
As yet, the vaccine is not yet available in the United States.
First, the U.S. The Food and Drug Administration approved the emergency use of Pfizer and Bioentech vaccines on Friday following the recommendation of its own vaccine advisers. The ACIP visited on Saturday and the CDC visited the U.S. Voted to allow the vaccine for use in and to recommend adding it to the vaccine schedule.
Now the CDC will have to decide whether to accept the ACIP recommendation. Once that happens, the vaccine can be given.
U.S. Officials with the federal government’s War Operations Act say they are wearing the vaccine to be dispatched for delivery on Monday.
‘End of Coronavirus Epidemic’
During Saturday’s meeting, ACIP members heard representations about people’s readiness to be vaccinated, who should and should not be vaccinated, and how it should be delivered to health care providers and the general public.
ACIP members said on Saturday that their evaluation of Pfizer and Bioentech’s coronavirus vaccine was independent and transparent.
“I believe that the process we have used here at ACE to reach this decision is transparent, science-based, takes into account equity and for the moment, it is the best we can do,” said ACIP member Dr. . Beth Bell, Clinical Professor of Global Health at the University of Washington.
Some members of the committee said they would take the vaccine, and recommend it to his family members.
“I would like to say that I voted for the vaccine because of the clear evidence of its effectiveness / safety profile and benefit-risk profile, based on our evidence and policy framework,” said Dr. Peter Sizzalgi, an Angels and ACIP member, said immediately after the committee’s vote.
Sizzalyagi said he really wanted to emphasize the need for a significant increase in government funding to implement the recommendation.
“So this is government funding for state and local public health institutions, and also funding for health systems and health providers,” Sizzalyagi said. “So I know that due to the increase and limited vaccine supply we will have a very hard and tough time ahead, but I am really hopeful that this is the beginning of the end of the coronavirus epidemic.”
.
